Cited by 390Clostridium difficile and Clostridium perfringens researchGut microbiota and healthGastrointestinal motility and disorders

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection

Open access

Hvas, Christian Lodberg, Dahl Jørgensen, Simon Mark, Jørgensen, Søren Peter, Storgaard, Merete, Lemming, Lars, Hansen, Mette Mejlby, Erikstrup, Christian, Dahlerup, Jens Frederik·2019·Gastroenterology

DOI 10.1053/j.gastro.2018.12.019

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND & AIMS: Fecal microbiota transplantation (FMT) is recommended for treatment of recurrent Clostridium difficile infection (rCDI). We performed a single-center randomized trial to compare the effects of FMT with those of fidaxomicin and vancomycin. METHODS: We studied consecutive adults with rCDI seen at a gastroenterology clinic in Denmark from April 5, 2016 through June 10, 2018. Patients were randomly assigned to a group that received FMT, applied by colonoscopy or nasojejunal tube, after 4-10 days of vancomycin (125 mg 4 times daily; FMTv; n = 24), 10 days of fidaxomicin (200 mg twice daily; n = 24), or 10 days of vancomycin (125 mg 4 times daily; n = 16). Patients who had rCDI after this course of treatment and patients who could not be randomly assigned to groups were offered rescue FMTv. The primary outcome was combined clinical resolution and a negative result from a polymerase chain reaction test for Clostridium difficile (CD) toxin 8 weeks after the allocated treatment. Secondary end points included clinical resolution at week 8. RESULTS: All 64 patients received their assigned treatment. The combination of clinical resolution and negative results from the test for CD were observed in 17 patients given FMTv (71%), 8 patients given fidaxomicin (33%), and 3 patients given vancomycin (19%; P = .009 for FMTv vs fidaxomicin; P = .001 for FMTv vs vancomycin; P = .31 for fidaxomicin vs vancomycin). Clinical resolution was observed in 22 patients given FMTv (92%), 10 patients given fidaxomicin (42%), and 3 patients given vancomycin (19%; P = .0002; P < .0001; P = .13). Results did not differ significantly between patients who received FMTv as their initial therapy and patients who received rescue FMTv. There was 1 serious adverse event that might have been related to FMTv. CONCLUSIONS: In a randomized trial of patients with rCDI, we found the FMTv combination superior to fidaxomicin or vancomycin based on end points of clinical and microbiological resolution or clinical resolution alone. ClinicalTrials.gov, number NCT02743234; EudraCT, j.no 2015-003004-24.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2018.12.019

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Fundamentals of Clinical Trials
Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015) · doi:10.1007/978-3-319-18539-2 · Cited by 2,237
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A. L., Golan, Y., Gorbach, S. L., Sears, P. S., & Shue, Y. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,610
Clostridium difficile Infection
Leffler, D. A., & LaMont, J. T. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1403772 · Cited by 1,501
European Society of Clinical Microbiology and Infectious Diseases: Update of the Treatment Guidance Document for Clostridium difficile Infection
Debast, S. B., Bauer, M. P., & Kuijper, E. J. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12418 · Cited by 1,241
European consensus conference on faecal microbiota transplantation in clinical practice
Cammarota, G., Ianiro, G., Tilg, H., Rajilić-Stojanović, M., Kump, P., Satokari, R., Sokol, H., Arkkila, P., Pintus, C., Hart, A., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-313017 · Cited by 1,207
Clostridium difficile infection in Europe: a hospital-based survey
Bauer, M. P., Notermans, D. W., BENTHEM, B. H. B. V., Brazier, J. S., Wilcox, M. H., Rupnik, M., Monnet, D. L., van Dissel, J. T., & Kuijper, E. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61266-4 · Cited by 1,049
Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea
Kyne, L., Warny, M., Qamar, A., & Kelly, C. P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03592-3 · Cited by 798
Documenta Geigy; scientific tables.
(1963) · JAMA · doi:10.1001/jama.1963.03700140139041 · Cited by 778

Show all 54 references

Research works printed but not linked: 1

2011, Detailed guidance on the collection, verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use (‘CT-3’). CELEX number 52011XC0611(01), Official Journal of the European Union

Sorted by citations

European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults
van Prehn, J., Reigadas, E., Vogelzang, E. H., Bouza, E., Hristea, A., Guery, B., Krutova, M., Norén, T., Allerberger, F., Coia, J. E., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.038 · Cited by 640
International consensus conference on stool banking for faecal microbiota transplantation in clinical practice
Cammarota, G., Ianiro, G., Kelly, C. R., Mullish, B. H., Allegretti, J. R., Kassam, Z., Putignani, L., Fischer, M., Keller, J. J., Costello, S. P., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-319548 · Cited by 506
Fecal microbiota transplantation: current challenges and future landscapes
Yadegar, A., Bar‐Yoseph, H., Monaghan, T. M., Pakpour, S., Severino, A., Kuijper, E. J., Smits, W. K., Terveer, E. M., Neupane, S., Nabavi-Rad, A., et al. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00060-22 · Cited by 397
Key determinants of success in fecal microbiota transplantation: From microbiome to clinic
Porcari, S., Benech, N., Valles-Colomer, M., Segata, N., Gasbarrini, A., Cammarota, G., Sokol, H., & Ianiro, G. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.03.020 · Cited by 331
The evolution of the use of faecal microbiota transplantation and emerging therapeutic indications.
Allegretti, J. R., Mullish, B. H., Kelly, C., & Fischer, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31266-8 · Cited by 358
Gut Microbiota Dysbiosis: Pathogenesis, Diseases, Prevention, and Therapy
Shen, Y., Fan, N., Ma, S., Cheng, X., Yang, X., & Wang, G. (2025) · MedComm · doi:10.1002/mco2.70168 · Cited by 404
Faecal microbiota transplantation for recurrent Clostridioides difficile infection: An updated systematic review and meta-analysis
Baunwall, S. M. D., Lee, M. M., Eriksen, M. K., Mullish, B. H., Marchesi, J. R., Dahlerup, J. F., & Hvas, C. L. (2020) · EClinicalMedicine · doi:10.1016/j.eclinm.2020.100642 · Cited by 319
Gut liver brain axis in diseases: the implications for therapeutic interventions
Yan, M., Man, S., Sun, B., Ma, L., Guo, L., Huang, L., & Gao, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01673-4 · Cited by 314
AGA Clinical Practice Guideline on Fecal Microbiota–Based Therapies for Select Gastrointestinal Diseases
Peery, A. F., Kelly, C. R., Kao, D. H., Vaughn, B. P., Lebwohl, B., Singh, S. S., Imdad, A., & Altayar, O. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.01.008 · Cited by 299
The microbiome in inflammatory bowel diseases: from pathogenesis to therapy
Liu, S., Zhao, W., Lan, P., & Mou, X. (2020) · Protein & Cell · doi:10.1007/s13238-020-00745-3 · Cited by 279
Challenge to the Intestinal Mucosa During Sepsis
Haußner, F., Chakraborty, S., Halbgebauer, R., & Huber-Lang, M. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00891 · Cited by 233
Leveraging diet to engineer the gut microbiome
Wolter, M., Grant, E. T., Boudaud, M., Steimle, A., Pereira, G. V., Martens, E. C., & Desai, M. S. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00512-7 · Cited by 211
Fecal microbiota transplantation therapy for Parkinson's disease: A preliminary study
Xue, L.-J., Yang, X.-Z., Tong, Q., Shen, P., Ma, S.-J., Wu, S.-N., Zheng, J.-L., & Wang, H.-G. (2020) · Medicine · doi:10.1097/md.0000000000022035 · Cited by 186
New Insights Into the Cancer–Microbiome–Immune Axis: Decrypting a Decade of Discoveries
Jain, T., Sharma, P., Are, A. C., Vickers, S. M., & Dudeja, V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.622064 · Cited by 187
Regulation, risk and safety of Faecal Microbiota Transplant
Merrick, B., Allen, L., Masirah M Zain, N., Forbes, B., Shawcross, D. L., & Goldenberg, S. D. (2020) · Infection Prevention in Practice · doi:10.1016/j.infpip.2020.100069 · Cited by 171
Fecal microbiota transplantation beyond Clostridioides difficile infections
Wortelboer, K., Nieuwdorp, M., & Herrema, H. (2019) · eBioMedicine · doi:10.1016/j.ebiom.2019.05.066 · Cited by 163
Metabolic Influences of Gut Microbiota Dysbiosis on Inflammatory Bowel Disease
Sultan, S., El‐Mowafy, M., Elgaml, A., Ahmed, T. A., Hassan, H., & Mottawea, W. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.715506 · Cited by 170
Infections in the Elderly Critically-Ill Patients
Eşme, M., Topeli̇, A., Doğu, B. B., & Akova, M. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00118 · Cited by 157
Faecal microbiota transplantation for Clostridioides difficile: mechanisms and pharmacology
Khoruts, A., Staley, C., & Sadowsky, M. J. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0350-4 · Cited by 155
Fecal Microbiota Transplantation as New Therapeutic Avenue for Human Diseases
Biazzo, M., & Deidda, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11144119 · Cited by 172
Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial
Baunwall, S. M. D., Paaske, S. E., Hansen, M. M., Kelsen, J., Høyer, K. L., Rågård, N., Eriksen, L. L., Støy, S. H., Rubak, T., Damsgaard, E. M. S., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00276-x · Cited by 138
Gut Microbiota in Psoriasis
Buhaș, M. C., Gavrilaș, L. I., CANDREA, A. R., Cătinean, A., Mocan, A., Miere, D., & Tataru, A. D. (2022) · Nutrients · doi:10.3390/nu14142970 · Cited by 134
Delivery routes for faecal microbiota transplants: Available, anticipated and aspired
Gulati, M., Singh, S. K., Corrie, L., Kaur, I. P., & Chandwani, L. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104954 · Cited by 116
Incidence of Bloodstream Infections, Length of Hospital Stay, and Survival in Patients With Recurrent Clostridioides difficile Infection Treated With Fecal Microbiota Transplantation or Antibiotics
Ianiro, G., Murri, R., Sciumè, G. D., Impagnatiello, M., Masucci, L., Ford, A. C., Law, G. R., Tilg, H., Sanguinetti, M., Cauda, R., et al. (2019) · Annals of Internal Medicine · doi:10.7326/m18-3635 · Cited by 109
Gut Dysbiosis and Fecal Microbiota Transplantation in Autoimmune Diseases
Belvončíková, P., Marônek, M., & Gardlík, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810729 · Cited by 108
Clostridioides difficile: diagnosis and treatments
Guery, B. P., Galpérine, T., & Barbut, F. (2019) · BMJ · doi:10.1136/bmj.l4609 · Cited by 117
Epidemiology of community-acquired and recurrent Clostridioides difficile infection
Fu, Y., Luo, Y., & Grinspan, A. M. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211016248 · Cited by 103
Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile ( Clostridium difficile )
Minkoff, N. Z., Aslam, S., Medina, M., Tanner‐Smith, E. E., Zackular, J. P., Acra, S. A., Nicholson, M. R., & Imdad, A. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013871.pub2 · Cited by 113
From Donor to Patient: Collection, Preparation and Cryopreservation of Fecal Samples for Fecal Microbiota Transplantation
Nicco, C., Paule, A., Konturek, P. C., & Edeas, M. A. (2020) · Diseases · doi:10.3390/diseases8020009 · Cited by 91
Gut microbial metabolome in inflammatory bowel disease: From association to therapeutic perspectives
Li, M., Yang, L., Mu, C., Sun, Y., Gu, Y., Chen, D., Liu, T., & Cao, H. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.03.038 · Cited by 89
Therapies to modulate gut microbiota: Past, present and future
Gupta, A., Saha, S., & Khanna, S. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i8.777 · Cited by 84
Gut Microbiota: Its Potential Roles in Pancreatic Cancer
Li, Q., Jin, M., Liu, Y., & Jin, L. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.572492 · Cited by 89
Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines
Bishop, E. J., & Tiruvoipati, R. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac404 · Cited by 92
Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy
Yang, Y., An, Y., Dong, Y., Chu, Q., Wei, J., Wang, B., & Cao, H. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.104967 · Cited by 84
Research progress on the relationship between intestinal microecology and intestinal bowel disease
Fu, Q.-H., Song, T., Ma, X., & Cui, J. (2022) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12262 · Cited by 76
Microbiota-mediated protection against antibiotic-resistant pathogens
Panwar, R., Sequeira, R. P., & Clarke, T. B. (2021) · Genes and Immunity · doi:10.1038/s41435-021-00129-5 · Cited by 74
Insights into the Evolving Epidemiology of Clostridioides difficile Infection and Treatment: A Global Perspective
Liu, C. S., Monaghan, T. M., Yadegar, A., Louie, T., & Kao, D. H. (2023) · Antibiotics · doi:10.3390/antibiotics12071141 · Cited by 73
Fecal Microbiota Transplantation and Other Gut Microbiota Manipulation Strategies
Quaranta, G., Guarnaccia, A., Fancello, G., Agrillo, C., Iannarelli, F., Sanguinetti, M., & Masucci, L. (2022) · Microorganisms · doi:10.3390/microorganisms10122424 · Cited by 72
A network meta‐analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent Clostridium difficile infection
Rokkas, T., Gisbert, J. P., Gasbarrini, A., Hold, G. L., Tilg, H., Malfertheiner, P., Mégraud, F., & O'Morain, C. A. (2019) · United European Gastroenterology Journal · doi:10.1177/2050640619854587 · Cited by 69
The role of the gut microbiota in tumor, immunity, and immunotherapy
Xie, Y., & Liu, F. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1410928 · Cited by 75
Hair regrowth following fecal microbiota transplantation in an elderly patient with alopecia areata: A case report and review of the literature
Xie, W.-R., Yang, X.-Y., Xia, H. H.-X., Wu, L.-H., & He, X.-X. (2019) · World Journal of Clinical Cases · doi:10.12998/wjcc.v7.i19.3074 · Cited by 67
Faecal microbiota transplantation for Clostridioides difficile infection: Four years’ experience of the Netherlands Donor Feces Bank
Terveer, E. M., Vendrik, K. E. W., Ooijevaar, R. E., van Lingen, E., Boeije‐Koppenol, E., van Nood, E., Goorhuis, A., Bauer, M. P., van Beurden, Y. H., Dijkgraaf, M. G. W., et al. (2020) · United European Gastroenterology Journal · doi:10.1177/2050640620957765 · Cited by 68
Advancing therapeutics for recurrent clostridioides difficile infections: an overview of vowst’s FDA approval and implications
Jain, N., Umar, T. P., Fahner, A.-F., & Ģībietis, V. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2232137 · Cited by 71
Exposure to prescribed medication in early life and impacts on gut microbiota and disease development
Huang, H., Jiang, J., Wang, X., Jiang, K., & Cao, H. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102428 · Cited by 71
The Role of Microbiota in Primary Sclerosing Cholangitis and Related Biliary Malignancies
Özdirik, B., Müller, T., Wree, A., Tacke, F., & Sigal, M. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136975 · Cited by 62
Adverse events in fecal microbiota transplantation: a systematic review and meta-analysis
Rapoport, E. A. (2022) · Annals of Gastroenterology · doi:10.20524/aog.2022.0695 · Cited by 59
Gut Microbiota and Clostridium difficile: What We Know and the New Frontiers
Piccioni, A., Rosa, F., Manca, F., Pignataro, G., Zanza, C., Savioli, G., Covino, M., Ojetti, V., Gasbarrini, A., Franceschi, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113323 · Cited by 64
Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy
Airola, C., Severino, A., Porcari, S., Fusco, W. G., Mullish, B. H., Gasbarrini, A., Cammarota, G., Ponziani, F. R., & Ianiro, G. (2023) · Antibiotics · doi:10.3390/antibiotics12050868 · Cited by 66
Aktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline
Kucharzik, T. F., Dignass, A. U., Atreya, R. N., Bokemeyer, B., Esters, P., Herrlinger, K. R., Kannengießer, K., Kienle, P., Langhorst, J., Lügering, A., et al. (2020) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1296-3444 · Cited by 63
Limosilactobacillus mucosae-derived extracellular vesicles modulates macrophage phenotype and orchestrates gut homeostasis in a diarrheal piglet model
Li, J., Feng, S., Wang, Z., He, J., Zhang, Z., Zou, H., Wu, Z., Liu, X., Hong Kui, W. E. I., & Tao, S. (2023) · npj Biofilms and Microbiomes · doi:10.1038/s41522-023-00403-6 · Cited by 61
Enterobacteriaceae Growth Promotion by Intestinal Acylcarnitines, a Biomarker of Dysbiosis in Inflammatory Bowel Disease
Lemons, J. M. S., Conrad, M. A., Tanes, C., Chen, J., Friedman, E. S., Roggiani, M., Curry, D., Chau, L., Hecht, A. L., Harling, L. C., et al. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.09.005 · Cited by 60
Updates in Treatment of Recurrent Clostridium difficile Infection
Singh, T., Bedi, P. S., Bumrah, K., Singh, J., Rai, M., & Seelam, S. (2019) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3854 · Cited by 54
Effectiveness and Safety of Colonic and Capsule Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection
Vaughn, B. P., Fischer, M., Kelly, C. R., Allegretti, J. R., Graiziger, C. T., Thomas, J., McClure, E. L., Kabage, A. J., & Khoruts, A. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.09.008 · Cited by 59
Randomised clinical trial: a 12‐strain bacterial mixture versus faecal microbiota transplantation versus vancomycin for recurrent Clostridioides difficile infections
Rode, A. A., Chehri, M., Krogsgaard, L. R., Heno, K. K., Svendsen, A. T., Ribberholt, I., Helms, M., Engberg, J., Schønning, K., Tvede, M., et al. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16309 · Cited by 51
Fecal Microbiota Transplantation in Chronic Pouchitis: A Randomized, Parallel, Double-Blinded Clinical Trial
Karjalainen, E. K., Renkonen‐Sinisalo, L., Satokari, R. M., Mustonen, H. K., Ristimaki, A. P., Arkkila, P. E. T., & Lepistö, A. (2021) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izab001 · Cited by 51
Long-distance microbial mechanisms impacting cancer immunosurveillance
Zitvogel, L., Fidelle, M., & Kroemer, G. (2024) · Immunity · doi:10.1016/j.immuni.2024.07.020 · Cited by 56
Fecal microbiota transplantation: great potential with many challenges
Kellermayer, R. (2019) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.05.10 · Cited by 52
Update on Treatment of Clostridioides difficile Infection
Cho, J. M., Pardi, D. S., & Khanna, S. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.08.006 · Cited by 48
Gut Microbiome as a Target of Intervention in Inflammatory Bowel Disease Pathogenesis and Therapy
Hetta, ‏. F., Ramadan, Y. N., Alharbi, A. A., Alsharif, S. M., Alkindy, T. T., Alkhamali, A., Albalawi, A. S., & El‐Amin, H. (2024) · Immuno · doi:10.3390/immuno4040026 · Cited by 54
Evolution of fecal microbiota transplantation in methodology and ethical issues
Zhang, F., Zhang, T., Zhu, H., & Borody, T. J. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.04.004 · Cited by 45
Improving Risk–Benefit in Faecal Transplantation through Microbiome Screening
Papanicolas, L. E., Gordon, D., Wesselingh, S. L., & Rogers, G. B. (2020) · Trends in Microbiology · doi:10.1016/j.tim.2019.12.009 · Cited by 47
Clostridioides difficile and Gut Microbiota: From Colonization to Infection and Treatment
Spigaglia, P. (2024) · Pathogens · doi:10.3390/pathogens13080646 · Cited by 53
Lactobacillus vaginalis alleviates DSS induced colitis by regulating the gut microbiota and increasing the production of 3-indoleacrylic acid
Wang, Z., Tian, L., Liu, L., Xie, J., Tang, F., Pi, Y., Zhong, Y., He, Z., Zhang, W., & Zheng, C. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107663 · Cited by 45
The blood-brain barrier, a key bridge to treat neurodegenerative diseases
Hang, Z., Zhou, L., Xing, C., Wen, Y., & Du, H. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102070 · Cited by 46
Fecal microbiota transplantation (FMT) for C. difficile infection, just say ‘No’
Tan, X., & Johnson, S. (2019) · Anaerobe · doi:10.1016/j.anaerobe.2019.102092 · Cited by 42
Gut microbiota differs between treatment outcomes early after fecal microbiota transplantation against recurrent Clostridioides difficile infection
Wei, S., Bahl, M. I., Baunwall, S. M. D., Dahlerup, J. F., Hvas, C. L., & Licht, T. R. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2084306 · Cited by 43
Dissecting mechanisms of fecal microbiota transplantation efficacy in disease
Andary, C. M., Al, K. F., Chmiel, J. A., Gibbons, S., Daisley, B. A., Parvathy, S. N., Vareki, S. M., Bowdish, D. M. E., Silverman, M., & Burton, J. P. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.12.005 · Cited by 46
The Evolving Landscape of Fecal Microbial Transplantation
Shao, T., Hsu, R., Hacein-Bey, C., Zhang, W., Gao, L., Kurth, M. J., Zhao, H., Shuai, Z., & Leung, P. S. C. (2023) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-023-08958-0 · Cited by 43
A Randomized Controlled Trial of Efficacy and Safety of Fecal Microbiota Transplant for Preventing Recurrent Clostridioides difficile Infection
Drekonja, D. M., Shaukat, A., Huang, Y., Zhang, J. H., Reinink, A. R., Nugent, S. M., Dominitz, J. A., Davis‐Karim, A., Gerding, D. N., & Kyriakides, T. C. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae467 · Cited by 41
Danish national guideline for the treatment of Clostridioides difficile infection and use of faecal microbiota transplantation (FMT)
Baunwall, S. M. D., Dahlerup, J. F., Engberg, J., Erikstrup, C., Helms, M., Juel, M. A., Kjeldsen, J., Nielsen, H. L., Nilsson, A. C., Rode, A. A., et al. (2021) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2021.1922749 · Cited by 45
Systematic review with meta-analysis: encapsulated faecal microbiota transplantation – evidence for clinical efficacy
Cold, F., Baunwall, S. M. D., Dahlerup, J. F., Petersen, A. M., Hvas, C. L., & Hansen, L. H. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211041004 · Cited by 41
Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection — An observational cohort study
Polívková, S., Krůtová, M., Čapek, V., Sýkorová, B., & Beneš, J. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.11.004 · Cited by 40
Microbiome Engineering: A Promising Approach to Improve Coral Health
Li, J., Yang, Q., Dong, J., Sweet, M. J., Zhang, Y., Liu, C., Zhang, Y., Tang, X., Zhang, W., & Zhang, S. (2022) · Engineering · doi:10.1016/j.eng.2022.07.010 · Cited by 40
The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines
Mullish, B. H., Merrick, B., Quraishi, M. N., Bak, A., Green, C., Moore, D., Porter, R. J., Elumogo, N., Segal, J. P., Sharma, N., et al. (2024) · Journal of Hospital Infection · doi:10.1016/j.jhin.2024.03.001 · Cited by 42
Lactoferrin in the Prevention and Treatment of Intestinal Inflammatory Pathologies Associated with Colorectal Cancer Development
Cutone, A., Ianiro, G., Lepanto, M. S., Rosa, L., Valenti, P., di Patti, M. C. B., & Musci, G. (2020) · Cancers · doi:10.3390/cancers12123806 · Cited by 40
Intestinal Microbiota—A Promising Target for Antiviral Therapy?
Yang, M., Yang, Y., He, Q., Zhu, P., Liu, M., Xu, J., & Zhao, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.676232 · Cited by 41
La mujer en la publicidad
Peñamarín, C., & Frabetti, C. (1990) · Dialnet (Universidad de la Rioja) · Cited by 39
Bacteriophage-mediated manipulations of microbiota in gastrointestinal diseases
Haddad, L. E., Mendoza, J. F., & Jobin, C. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1055427 · Cited by 41
Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.2)
Kucharzik, T., Dignass, A., Atreya, R., Bokemeyer, B., Esters, P., Herrlinger, K., Kannengiesser, K., Kienle, P., Langhorst, J., Lügering, A., et al. (2024) · Zeitschrift für Gastroenterologie - German Journal of Gastroenterology · doi:10.1055/a-2271-0994 · Cited by 37
Gut Microbiota Modulation: Implications for Infection Control and Antimicrobial Stewardship
Tan, G. S. E., Tay, H. L., Tan, S. H., Lee, T. H., Ng, T. M., & Lye, D. C. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01458-z · Cited by 38
Proton Pump Inhibitors and Oral–Gut Microbiota: From Mechanism to Clinical Significance
Zhang, X., Li, Q., Xia, S., He, Y., Liu, Y., Yang, J., & Xiao, X. (2024) · Biomedicines · doi:10.3390/biomedicines12102271 · Cited by 37
The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines
Mullish, B. H., Merrick, B., Quraishi, M. N., Bak, A., Green, C., Moore, D., Porter, R. J., Elumogo, N., Segal, J. P., Sharma, N., et al. (2024) · Gut · doi:10.1136/gutjnl-2023-331550 · Cited by 40
The Role of Gut Microbiota in Gastrointestinal Immune Homeostasis and Inflammation: Implications for Inflammatory Bowel Disease
Bretto, E., Caviglia, G. P., Saracco, G. M., Bugianesi, E., & Ribaldone, D. G. (2025) · Biomedicines · doi:10.3390/biomedicines13081807 · Cited by 41
Impact of encapsulating a probiotic ( Pediococcus pentosaceus Li05) within gastro-responsive microgels on Clostridium difficile infections
Xie, J., Yao, M., Lu, Y., Yu, M., Han, S., McClements, D. J., Xiao, H., & Li, L. (2021) · Food & Function · doi:10.1039/d0fo03235b · Cited by 34
Fecal microbiota transplantation for recurrent Clostridioides difficile , safety, and pitfalls
Sandhu, A., & Chopra, T. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211053105 · Cited by 38
Randomised clinical trial: Faecal microbiota transplantation for irritable bowel syndrome with diarrhoea
Yau, Y. K., Su, Q., Xu, Z., Tang, W., Ching, J. Y. L., Mak, J. W. Y., Cheung, C. P., Fung, M., Ip, M., Chan, P. K. S., et al. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17703 · Cited by 34
The Progression of Microbiome Therapeutics for the Management of Gastrointestinal Diseases and Beyond
Allegretti, J. R., Khanna, S., Mullish, B. H., & Feuerstadt, P. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.05.004 · Cited by 35
The Route to Palatable Fecal Microbiota Transplantation
Fadda, H. M. (2020) · AAPS PharmSciTech · doi:10.1208/s12249-020-1637-z · Cited by 36
Intestinal Microbiota in Common Chronic Inflammatory Disorders Affecting Children
Torun, A., Hupalowska, A., Trzonkowski, P., Kierkuś, J., & Pyrzyńska, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.642166 · Cited by 40
S2k-Leitlinie Gastrointestinale Infektionen der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)
Manthey, C. F., Epple, H., Keller, K., Lübbert, C., Posovszky, C., Ramharter, M., Reuken, P. A., Suerbaum, S., Vehreschild, M. J. G. T., Weinke, T., et al. (2024) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2240-1428 · Cited by 32
Adverse events of fecal microbiota transplantation: a metaanalysis of high-quality studies
Michailidis, L. (2021) · Annals of Gastroenterology · doi:10.20524/aog.2021.0655 · Cited by 34
Update on microbiota-derived therapies for recurrent Clostridioides difficile infections
Benech, N., Barbut, F., Fitzpatrick, F., Krůtová, M., Davies, K., Druart, C., Cordaillat‐Simmons, M., Heritage, J. C., Guery, B. P., & Kuijper, E. J. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.12.007 · Cited by 31
Are There Potential Applications of Fecal Microbiota Transplantation beyond Intestinal Disorders?
Zhou, Y., Xu, H., Huang, H., Li, Y., Chen, H., He, J., Du, Y., Chen, Y., Zhou, Y., & Nie, Y. (2019) · BioMed Research International · doi:10.1155/2019/3469754 · Cited by 32
Long-term safety and efficacy of fecal microbiota transplantation in 74 children: A single-center retrospective study
Zou, B., Liu, S., Li, X., He, J., Dong, C., Ruan, M.-L., Xu, L., Bai, T., Huang, Z., & Shu, S. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.964154 · Cited by 31
Fecal Microbiota Transplantation in Gastrointestinal and Extraintestinal Disorders
Ianiro, G., Segal, J. P., Mullish, B. H., Quraishi, M. N., Porcari, S., Fabiani, G., Gasbarrini, A., & Cammarota, G. (2020) · Future Microbiology · doi:10.2217/fmb-2020-0061 · Cited by 31
Current Understanding of Equine Gut Dysbiosis and Microbiota Manipulation Techniques: Comparison with Current Knowledge in Other Species
Boucher, L., Leduc, L., Leclère, M., & Costa, M. (2024) · Animals · doi:10.3390/ani14050758 · Cited by 36
Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.1) – Februar 2023 – AWMF-Registriernummer: 021-009
Kucharzik, T., Dignass, A., Atreya, R., Bokemeyer, B., Esters, P., Herrlinger, K., Kannengiesser, K., Kienle, P., Langhorst, J., Lügering, A., et al. (2023) · Zeitschrift für Gastroenterologie - German Journal of Gastroenterology · doi:10.1055/a-2060-0935 · Cited by 24
A Comparison of Currently Available and Investigational Fecal Microbiota Transplant Products for Recurrent Clostridioides difficile Infection
Wang, Y., Hunt, A., Danziger, L. H., & Drwiega, E. N. (2024) · Antibiotics · doi:10.3390/antibiotics13050436 · Cited by 29
New Therapeutic Targets in Autoimmune Cholangiopathies
Gerussi, A., Luca, M. D., Cristoferi, L., Ronca, V., Mancuso, C., Milani, C., D’Amato, D., O'Donnell, S. E., Carbone, M., & Invernizzi, P. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00117 · Cited by 30
Cost-effectiveness of Fecal Microbiota Transplantation for First Recurrent Clostridioides difficile Infection
Aby, E. S., Vaughn, B. P., Enns, E. A., & Rajasingham, R. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac207 · Cited by 28

Authors: Hvas, C. L., Dahl Jørgensen, S. M., Jørgensen, S. P., Storgaard, M., Lemming, L., Hansen, M. M., Erikstrup, C., & Dahlerup, J. F.
Affiliations: Aarhus University Hospital (DK)
Corresponding author: Hvas, Christian Lodberg
ORCID: Hvas, Christian Lodberg
Jørgensen, Søren Peter
Storgaard, Merete
Hansen, Mette Mejlby
Erikstrup, Christian
Dahlerup, Jens Frederik
Venue: Gastroenterology
Publisher: Elsevier BV
Published: 2019-04
Volume: 156
Issue: 5
Pages: 1324-1332.e3
ISSN: 0016-5085 (ISSN-L)
DOI: 10.1053/j.gastro.2018.12.019
OpenAlex: W2907954911
Cited by: 390
References: 54
Citations by year: 2026: 36 · 2025: 44 · 2024: 58 · 2023: 58 · 2022: 57 · 2021: 46 · 2020: 57 · 2019: 33
FWCI: 36.80
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Locations: Gastroenterology (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Funders: Aalborg Universitet
Topics: Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Keywords: fecal microbiota transplantation, recurrent Clostridium difficile infection, fidaxomicin, vancomycin, clinical resolution, treatment comparison, adverse events, Clostridium difficile infection
MeSH terms: Fecal Microbiota Transplantation, Fidaxomicin, Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents, Clostridium Infections, Denmark, Female, Humans, Male, Middle Aged, Recurrence, Remission Induction, Time Factors, Vancomycin, Clostridioides difficile, Treatment Outcome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks